Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Current Deferred Revenue (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Current Deferred Revenue for 7 consecutive years, with $34.4 million as the latest value for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 153.13% year-over-year to $34.4 million; the TTM value through Dec 2025 reached $34.4 million, up 153.13%, while the annual FY2025 figure was $34.4 million, 153.13% up from the prior year.
  • Current Deferred Revenue hit $34.4 million in Q4 2025 for Kymera Therapeutics, up from $23.3 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $101.0 million in Q4 2021 and bottomed at $11.5 million in Q1 2025.
  • Average Current Deferred Revenue over 5 years is $45.4 million, with a median of $36.6 million recorded in 2022.
  • Year-over-year, Current Deferred Revenue crashed 70.91% in 2023 and then skyrocketed 153.13% in 2025.
  • Kymera Therapeutics' Current Deferred Revenue stood at $101.0 million in 2021, then plummeted by 65.1% to $35.3 million in 2022, then rose by 7.44% to $37.9 million in 2023, then tumbled by 64.16% to $13.6 million in 2024, then surged by 153.13% to $34.4 million in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $34.4 million, $23.3 million, and $40.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.